Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Cancer Drugs Fund Reforms Get Cautious Welcome, But More Needed

Executive Summary

NHS England has issued new guidelines on how cancer drugs will be appraised and funded in the UK, including the operation of the controversial Cancer Drugs Fund (CDF), which is being replaced by a new fund controlled by the HTA NICE from the end of July this year.

You may also be interested in...



New UK Cancer Drugs Fund Dismays Pharma, Charities

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation. Pharma companies believe they will have to shoulder additional financial risks while patients will still not get full access to the medicines they need.

UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.

Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction

Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel